Palvella Therapeutics, Inc. PVLA
153.18 USD -10.76 (-6.56%)
At closeNov 12, 2026, 4:00 PM EST
153.18 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
152.13 Day range 165.16
72.23 52-week range 179.95
- YTD
- +46.35%
- 1 year
- +87.86%
News
defenseworld.net Palvella Therapeutics, Inc. $PVLA Stock Bought by Alps Advisors Inc. Alps Advisors Inc. lifted its position in shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA) by 33.0% in the third quarter, according to the company in its most recent 13F filing with the…
defenseworld.net 2,882 Palvella Therapeutics, Inc. $PVLA Shares Bought by Calamos Advisors LLC Calamos Advisors LLC raised its stake in shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA) by 27.5% during the third quarter, according to the company in its most recent 13F filing with the SEC.…
benzinga.com Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243 Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $232 to $243.
seekingalpha.com Palvella Therapeutics, Inc. (PVLA) Q3 2026 Earnings Call Transcript Palvella Therapeutics, Inc. ( PVLA ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Bohan Wei - Vice President of Corporate Development & New Product Planning Wesley Kaupinen…
benzinga.com Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232 Oppenheimer analyst Trevor Allred maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $210 to $232.
marketbeat.com What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call Palvella Therapeutics NASDAQ: PVLA is preparing for a potential U.S. launch of QTORIN rapamycin after the Food and Drug Administration accepted its application for the treatment of microcystic…
benzinga.com Palvella Therapeutics Q3 2026 Earnings Call Transcript Palvella Therapeutics (NASDAQ:PVLA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Palvella Therapeutics Q3 EPS $(1.70) Beats $(1.82) Estimate Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(1.82) by 6.59 percent. This is a 65.05 percent decrease over losses…
globenewswire.com Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027
globenewswire.com Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference WAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…
globenewswire.com Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026 WAYNE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…
globenewswire.com Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and…
marketbeat.com Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands Palvella Therapeutics NASDAQ: PVLA is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt…
benzinga.com William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating.
globenewswire.com Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding
globenewswire.com Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…
benzinga.com Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday Analysts raised targets for CRBG, MTN, CRM and FSLR, while cutting targets for PVLA, SPOT and AMZN; CRM and FSLR were upgraded.
benzinga.com HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246 HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.
seekingalpha.com Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger Palvella Therapeutics, Inc. advances QTORIN rapamycin for microcystic lymphatic malformations, completing NDA submission with strong Phase 3 data and FDA rolling review. Regulatory risk is now…
benzinga.com Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations The award follows FDA review of Palvella’s annual performance progress report, which included results from the Phase 3 SELVA trial. In February 2026, Palvella announced positive topline results from…
globenewswire.com U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved
globenewswire.com Palvella Therapeutics Appoints James R. Treat, M.D. Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas
globenewswire.com Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…
globenewswire.com Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with…
defenseworld.net Bank of America Corp DE Has $4.73 Million Holdings in Palvella Therapeutics, Inc. $PVLA Bank of America Corp DE grew its stake in shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA) by 25.4% during the first quarter, according to the company in its most recent disclosure with the SEC.…
seekingalpha.com Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and…
marketbeat.com Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN…
defenseworld.net Palvella Therapeutics Q2 Earnings Call Highlights Palvella Therapeutics (NASDAQ: PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second…
benzinga.com Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.…- benzinga.com Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(1.14) by 33.33 percent. This is a 76.74 percent decrease over…
benzinga.com Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guidance. Other gainers: UTZ, AEHR, PKE, FWRD, HELP, SECZ, DOCN, TRAX, PVLA, COIN.
benzinga.com Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submittedFDA previously granted…
benzinga.com Palvella Therapeutics Announces FDA Rolling Review Of Its New Drug Application For Qtorin Rapamycin For The Treatment Of Microcystic Lymphatic Malformations FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submittedPalvella remains on…
benzinga.com Palvella Therapeutics Completes Pre-NDA Meeting With FDA For QTORIN 3.9% Rapamycin Anhydrous Gel In Microcystic Lymphatic Malformations; On Track To Submit NDA In H2 Of 2026 Palvella remains on track to submit an NDA in the second half of 2026Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking,…- benzinga.com Palvella Therapeutics Receives U.S. Patent For Its Licensed QTORIN Pitavastatin Program For Porokeratosis Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering…
- benzinga.com Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.
- benzinga.com Palvella Therapeutics Presents New Clinical Data From Phase 3 SELVA And Phase 2 TOIVA Studies At ISSVA World Congress 2026 In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as "Much Improved" (+2) or "Very Much Improved" (+3) on the Microcystic Lymphatic Malformation Investigator Global…
- benzinga.com Palvella Therapeutics Presents New Data From Phase 2 TOIVA Trial Of QTORIN Rapamycin In Patients With Cutaneous Venous Malformations At Annual Meeting Of SID 100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding)…
- benzinga.com Palvella Therapeutics Receives Approval To Uplist To Nasdaq Global Market The transfer is effective at the opening of trading on Wednesday, May 13, 2026. The Company's common stock will continue to trade under its existing ticker symbol, "PVLA."The Nasdaq Global Market has…
benzinga.com Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220 Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.- benzinga.com Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(0.93) by 29.03 percent. This is a 62.16 percent decrease over…
- benzinga.com Palvella Announces First Patients Dosed In LOTU, Multicenter Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Clinically Significant Angiokeratomas Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the…
- benzinga.com Palvella Therapeutics To Highlight Results From Phase 3 SELVA And Phase 2 TOIVA Studies Of QTORIN Rapamycin At ISSVA World Congress 2026 James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ETWAYNE, Pa., April…
- benzinga.com Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240 Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.
- benzinga.com Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.29 percent. This is a 79.89 percent increase over…
benzinga.com Earnings Scheduled For March 31, 2026 - benzinga.com Palvella Therapeutics Publishes Comprehensive Review Article Titled Microcystic and Macrocystic Lymphatic Malformations: Distinct Genetics And Clinical Strategies Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients…
- benzinga.com HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270 HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $255 to $270.
- benzinga.com Palvella Therapeutics Secures European Patent Covering Lead QTORIN Rapamycin Gel Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella's lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and…
- benzinga.com Mizuho Maintains Outperform on Palvella Therapeutics, Raises Price Target to $250 Mizuho analyst Graig Suvannavejh maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $205 to $250.